Copaxone

Commenting on Mylan N.V. (NASDAQ: MYL), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. That said, the firm thinks Mylan's chances are better than current market expectations. Analysts...

Offering its insight into the formulary coverage of multiple sclerosis drugs for 2017, Bernstein said in a note released on Thursday it sees stabilization of formulary coverage after a year of tightening in 2016. Treatment Options MS is a neurodegenerative disease affecting young adults,...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Monday after the bell that its president and CEO Erez Vigodman will step down, effective immediately. The company also said its chairman since January 2015 Yitzhak Peterburg will assume the role of president and CEO on an interim...

Oppenheimer analysts have issued an intraday note responding to a district court's ruling Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) Copaxone 40mg patents “invalid based on obviousness.” The court ruling likely paves the way for generics to enter the market for the multiple...

“The district court ruled against Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) in the Copaxone 40mg patent case, invalidating each of the four patents in the case,” Deutsche Bank’s Gregg Gilbert said in a note, while maintaining a Buy rating on the company, with a price...

Orphan drugs, drugs intended to prevent, diagnose or treat rare diseases/disorders, are huge sellers for the pharmaceutical industry. NPR, citing data from EvaluatePharma, noted that seven of the 10 best-selling drugs in the United States throughout 2015 were given an orphan drug status. The main...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) hit a new 52-week low of $37.25 on Tuesday after the company reported its third-quarter results and provided a concerning outlook for the full year given some concerns over its specialty drugs. The stock rebounded slightly on Wednesday...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) reduced its Q4 and FY 2016 outlook. This could be an indication of greater weakness in generics in 2017 and an increased chance of the 40mg Copaxone generic being launched, Jefferies’ David Steinberg said in a report. Steinberg downgraded...

Credit Suisse analyst Vamil Divan upgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) from Neutral to Outperform, while lowering the target price from $59 to $52 (representing a 23 percent upside). Divan cited the company's selloff since May as the key reason for the upgrade, adding that...

U.S. stocks declined for the second straight day after investors and traders digested disappointing earnings from retailers and economic reports were disappointing. The Dow suffered a triple-digit point loss and declined one percent after the retailer giant Wal-Mart failed to "wow" investors....

U.S. stocks were little moved to start off the month of May as investors and traders are cautious before April's nonfarm payrolls report are released on Friday. The consensus estimate for Friday's figure stands at 215,000 which would trump March's 192,000 number. “This is a really important...